Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Insomnia
- Main trialPhase 3
- “Insomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep. Consequences of insomnia include daytime sleepiness, poor memory function, decline in concentration with negative impacts on social and work activities. Although medical cannabis and cannabis products are widely used worldwide for the management of symptoms associated with insomnia, there is little clinical data available to support the efficacy or utility of CBD in the management of sleep disorders. The proposed study will assess whether nightly doses of 75mg…”In the company’s words, NCT05840822 on ClinicalTrials.gov
Other drugs for Insomnia
- RamelteonNanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- SolriamfetolAxsome Therapeutics, Inc. · Phase 3
- SuvorexantMerck & Co. · Phase 3
- TasimelteonVanda Pharmaceuticals · Phase 3
- HS-10506Hansoh · Phase 3
- SOM001-ASomnum Pharma Inc. · Phase 2
Coming up1
- 30 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Sep 2027 | Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026